Dr Catherine M Broome considers when to suspect CAD, and the steps needed to confirm a diagnosis, the impact of poor sample handling and delays to diagnosis, as well as the importance of real-world data in informing ongoing management of CAD.1/2 Next Interview
Dr Ilene Weitz outlines the role of complement inhibitors as an alternative treatment option in the evolving treatment landscape of CAD, and how to use specific markers to tailor treatment for individual patients.2/2 Take CE/CME Test
Overview & Learning Objectives
In this activity, US-based experts discuss best practice for diagnosing cold agglutinin disease (CAD) and how real-world data can inform our understanding of the natural history of the disease, as well as the current and emerging treatment options, and how we can use specific markers to tailor therapy and measure outcomes in patients with CAD.
This activity is jointly provided by USF Health and touchIME. read more
This activity has been designed to meet the educational needs of haematologists and haematologist-oncologists involved in the management of patients with cold agglutinin disease.
USF Health adheres to the Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to influence content have disclosed to USF Health any financial relationship with an ineligible organization. USF Health has reviewed and mitigated all relevant financial relationships related to the content of the activity. The relevant financial relationships are listed below. All individuals not listed have no relevant financial relationships.
Dr Catherine M Broome discloses: Advisory board/panel fees from Alexion, Annexon Biosciences, Argenx, Incyte and Sanofi. Consultancy fees from Star Therapeutics.
Dr Ilene Ceil Weitz discloses: Advisory board/panel fees from Alexion, Apellis, Novartis and Sanofi. Speaker’s bureau fees from Alexion.
Caitlin Papa, APRN has no relevant financial relationships to disclose.
Touch Medical Directors
Kathy Day and Sadaf Kazi have no financial interests/relationships or affiliations in relation to this activity.
USF Health Office of Continuing Professional Development and touchIME staff have no financial interests/relationships or affiliations in relation to this activity.
Requirements for Successful Completion
In order to receive credit for this activity, participants must review the content and complete the post-test and evaluation form. Statements of credit are awarded upon successful completion of the post-test and evaluation form.
If you have questions regarding credit please contact firstname.lastname@example.org.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through a joint providership of USF Health and touchIME. USF Health is accredited by the ACCME to provide continuing medical education for physicians.
USF Health designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS) – European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
Advanced Practice Providers
Physician Assistants may claim a maximum of 0.75 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 CreditTM from organizations accredited by ACCME or a recognized state medical society.
The AANPCP accepts certificates of participation for educational activities approved for AMA PRA Category 1 CreditTM by ACCME-accredited providers. APRNs who participate will receive a certificate of completion commensurate with the extent of their participation.
Date of original release: 10 October 2022. Date credits expire: 10 October 2023.
If you have any questions regarding credit please contact email@example.com.
After watching this activity, participants should be better able to:
- Outline strategies for the accurate diagnosis of cold agglutinin disease
- Evaluate the current and emerging treatment options for patients with cold agglutinin disease using the latest data
- Assess potential strategies for individualizing the treatment for patients with cold agglutinin disease